About Us

Nebulabio is a specialized discovery partner providing end-to-end, custom peptide discovery services for therapeutic, diagnostic, and research applications. Our mission is to empower innovation by transforming complex biological targets into high-potential peptide leads. We combine deep expertise in peptide chemistry, molecular biology, and screening technologies with a rigorous, platform-driven approach. Recognizing the unique advantages of peptides—high specificity, favorable safety profiles, and synthetic accessibility—we collaborate closely with clients across academia, biotechnology, and pharmaceutical sectors to navigate the discovery journey. From initial target assessment and library design to the delivery of validated, optimized lead candidates, our team is dedicated to accelerating your program with scientific excellence, transparency, and a commitment to success.

☞Introduction of Peptide Ligands

Peptide ligands are short chains of amino acids (typically 5-50 residues) designed to bind with high affinity and specificity to a target molecule, such as a protein receptor, enzyme, or nucleic acid. They occupy a crucial niche between small molecules and biologics (like antibodies), offering a unique blend of properties:

• High Specificity & Low Toxicity: Peptides can achieve exquisite target selectivity by mimicking natural protein-protein interaction interfaces, often leading to fewer off-target effects.

• Chemical Diversity & Tunability: The vast combinatorial space of natural and non-natural amino acids allows for the creation of highly diverse libraries. Peptides are readily optimized for improved potency, stability, and pharmacokinetic properties through chemical modification.

• Synthetic & Manufacturing Advantages: Peptides are produced via precise chemical synthesis (Solid-Phase Peptide Synthesis, SPPS), ensuring batch-to-batch consistency and enabling the incorporation of non-standard moieties (e.g., D-amino acids, fluorophores, or cytotoxic payloads).

Peptide ligands serve as powerful tools for target validation, diagnostic probe development, and as direct therapeutic candidates for diseases where modulating protein-protein interactions is key.

Figure1.There are the US Food and Drug Administration (FDA)-approved peptide drugs and those in clinical trials, highlighting recent advances in peptide-based drug discovery.

☞The Peptide Discovery Process

Our discovery process is a multi-stage, iterative funnel designed to identify and optimize the most promising peptide leads for your specific application.

①Target Analysis & Strategy Design: We begin with a deep dive into your target’s biology and desired functional outcome (e.g., inhibition, activation, targeted delivery). This informs the selection of the optimal discovery platform (phage display, combinatorial chemistry) and the design of focused or diverse peptide libraries.

②Library Construction & Screening:

• Phage Display Peptide Libraries: We utilize large, diverse libraries of random peptides displayed on filamentous phage surfaces. These libraries are subjected to multiple rounds of in vitro "biopanning" against your immobilized target to enrich for strong binders.

• One-Bead-One-Compound (OBOC) Combinatorial Libraries: For synthetic libraries, we employ high-throughput OBOC techniques, where millions of unique peptides are synthesized on individual resin beads. Beads displaying target-binding peptides are isolated and decoded.

③Hit Identification & Sequencing: Positive hits from screening are isolated. For phage display, the DNA encoding the peptide is sequenced. For synthetic libraries, mass spectrometry or micro-sequencing is used to determine the amino acid sequence.

④Hit Validation & Characterization: Initial hits are chemically synthesized and purified. Their binding affinity (measured by SPR, BLI, or ELISA), specificity (against counter-targets), and preliminary stability are assessed.

⑤Lead Optimization: Promising hits undergo systematic optimization. This stage may include:

• Alanine Scanning: To identify critical residues for binding.

• Sequence Truncation & Modification: To improve potency and metabolic stability.

• Peptide Stapling/Cyclization: To confer structural rigidity, enhance proteolytic resistance, and improve cell permeability.

• Conjugation: To link peptides to carriers, drugs (for drug conjugates), or imaging agents.

⑥Functional & In Vitro Assays: Optimized lead peptides are tested in relevant biological assays to confirm the desired functional activity (e.g., enzyme inhibition, receptor antagonism/agonism, cell internalization).

☞Nebulabio Service Process & Workflow

Our peptide discovery service follows a well-defined, four-phase workflow designed to ensure scientific rigor, clear communication, and successful progression from concept to lead candidate. Each phase is characterized by specific activities, deliverables, and client touchpoints, ensuring full transparency and collaborative project management.

 Phase 1: Design & Initiation 

This foundational phase focuses on planning and strategy. It begins with an in-depth Project Consultation where our scientists work closely with you to understand your target biology, desired peptide function (e.g., inhibitor, binder, cell-penetrating), and final application (therapeutic, diagnostic, research). Based on this, we perform a Target Analysis and proceed to Strategy & Library Design. Here, we determine the optimal discovery platform (e.g., phage display for linear/constrained peptides, OBOC for focused chemical libraries) and design the library parameters (length, diversity, inclusion of non-natural amino acids). The deliverable is a detailed, mutually agreed-upon Project Plan outlining the technical approach, timeline, and success criteria.

 Phase 2: Discovery & Screening 

In this experimental core phase, we execute the designed plan. Library Construction involves generating the physical peptide library—cloning and producing the phage library or performing parallel synthesis for the OBOC library. This library then undergoes High-Throughput Selection/Biopanning, where it is exposed to the immobilized target under defined stringency conditions over multiple rounds to enrich for high-affinity binders. Finally, Hit Identification & Sequencing involves isolating individual positive clones or beads. For phage display, the peptide-encoding DNA is sequenced; for synthetic libraries, peptides are decoded via mass spectrometry. The output is a List of Primary Hit Sequences with initial binding confirmation data.

 Phase 3: Validation & Optimization 

This phase transforms raw hits into refined leads. First, Hit Synthesis & Primary Validation involves chemically synthesizing and purifying the identified peptide hits. Their binding to the target is validated using a primary method (e.g., ELISA). Next, Lead Optimization is performed on the most promising candidates. This may include alanine scanning, sequence truncation, cyclization, or stapling to improve affinity, stability, and other drug-like properties. Finally, optimized leads undergo In-Depth Characterization, where binding kinetics (SPR/BLI), specificity against related targets, and in vitro stability (e.g., in serum) are rigorously assessed. The deliverable is a Characterization Report detailing the properties of several optimized lead candidates.

 Phase 4: Delivery 

The final phase ensures the leads are suitable for your next steps. We provide Functional Assay Support, which can include testing the lead peptides in your custom assay or in standardized in vitro functional assays (e.g., enzyme inhibition, cell-based activity) to confirm the desired biological effect. The project culminates in the Final Report & Lead Candidate Delivery. You receive a comprehensive data package documenting the entire discovery journey, along with tangible materials—milligram quantities of the purified, characterized lead peptide(s)—ready for your downstream development or research applications.

☞Our Service Features

• Integrated Platform Approach: We offer seamless integration of biological display technologies (Phage Display) and synthetic combinatorial chemistry (OBOC), allowing us to select the most effective path for each target class.

• Focus on "Drug-Like" Peptides: Our discovery and optimization strategies are specifically geared towards identifying peptides with therapeutic potential, prioritizing properties such as serum stability, solubility, and cell permeability from the early stages.

• Expertise in Peptide Engineering: We specialize in advanced structural optimization techniques, including peptide stapling, cyclization, and the incorporation of non-natural amino acids to overcome traditional peptide limitations.

• High-Throughput & Microscale Synthesis: Our capabilities enable the rapid synthesis and screening of vast peptide libraries, accelerating the path from concept to candidate.

• Application-Tailored Discovery: Whether your goal is to develop an imaging probe, a targeted delivery vehicle, a therapeutic antagonist, or a simple binding reagent, we tailor the discovery criteria and screening pressures to match the final application.

☞Why Choose Nebulabio?

• End-to-End Capability & Deep Expertise: As a dedicated peptide discovery partner, we offer unparalleled depth of experience across the entire value chain, from library design to optimized lead. Our scientists are experts in both the chemistry and biology of peptides.

• Proven Technology Platform & Success Record: Our robust and validated phage display and combinatorial chemistry platforms have a track record of delivering functional leads against a wide array of challenging targets, including protein-protein interaction surfaces.

• Collaborative Partnership Model: We function as an extension of your R&D team. You will have a dedicated project manager and direct access to our scientists, ensuring alignment, transparency, and agile decision-making throughout the project lifecycle.

• Commitment to Data Quality & IP Security: We deliver comprehensive, publication-ready data packages with each milestone. We operate under strict confidentiality agreements with clear IP protocols, ensuring your discoveries are fully protected.

• Accelerated Timelines: Our optimized, parallelized workflows and deep expertise significantly reduce the time required to progress from target to validated lead candidate, helping you advance your research or development program faster.

Choose Nebulabio as your peptide discovery partner to leverage a unique combination of technological sophistication, scientific rigor, and a partnership-focused approach designed to unlock the full potential of peptide therapeutics and reagents for your most ambitious projects.